Gemcitabine based trimodality treatment in patients with muscle invasive bladder cancer: May neutrophil lymphocyte and platelet lymphocyte ratios predict outcomes?


HÜRMÜZ P. , ÖZYİĞİT G. , Kilickap S., BEDÜK ESEN Ç. S. , AKDOĞAN B. , Ozen H., ...More

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, vol.39, no.6, 2021 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 6
  • Publication Date: 2021
  • Doi Number: 10.1016/j.urolonc.2020.11.006
  • Title of Journal : UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Abstract

Purpose: Cisplatin based chemoradiation has been commonly used as a definitive treatment for muscle-invasive bladder cancer (MIBC). The aim of the current study is to evaluate oncologic results and toxicity profile of bladder-sparing treatment with external beam radiotherapy (EBRT) and gemcitabine chemotherapy (ChT) in patients with MIBC.